Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Template:SubstanceBox/Buprenorphine: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older edit
>Unity
m Text replacement - "MolecularStructureCaption=The skeletal formula" to "MolecularStructureCaption=Molecular structure"
>Isaak
Make insufflated route expanded by default.
 
(11 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{SubstanceBox
{{SubstanceBox


     <!-- Table Properties -->
     <!-- Special Parameters -->
     |MaterialTable_MaxWidth=200px
    |displayClasses={{{displayClasses|}}}
     |MaterialTable_MaxWidth=250px
     |MaterialTable_Title={{PAGENAME}}
     |MaterialTable_Title={{PAGENAME}}


Line 33: Line 34:
     <!-- Structure -->  
     <!-- Structure -->  
     |MolecularStructureCaption=Molecular structure of buprenorphine
     |MolecularStructureCaption=Molecular structure of buprenorphine
     |SkeletalImageFile=File:Buphrenorphine.png
     |SkeletalImageFile=File:Buprenorphine.svg
     |SkeletalImageWidth=245px
     |SkeletalImageWidth=245px
     |3DImageFile=File:Buprenorphine_molecule_from_xtal_ball.png
     |3DImageFile=
     |3DImageWidth=200px
     |3DImageWidth=200px
    
    
   <!-- Nomenclature -->
   <!-- Nomenclature -->
     |NameCommon=Buprenex, Subutex, Butrans, Cizdol
     |NameCommon=[[common name::Buprenex]], [[common name::Subutex]], [[common name::Butrans]], [[common name::Cizdol]], [[common name::Addnok]], [[common name::Transtec]]
     |NameSubstitution=
     |NameSubstitution=
     |NameSystematic=(2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
     |NameSystematic=(2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
Line 50: Line 51:


     |InsufflatedROA=true
     |InsufflatedROA=true
     |InsufflatedROA_Collapsed=
     |InsufflatedROA_Collapsed=false
     |InsufflatedROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
     |InsufflatedROA_Caption=
    |InsufflatedROA_Bioavailability=48%
    |InsufflatedROA_Bioavailability=48%<ref name="Eriksen1989">{{cite journal | vauthors=((Eriksen, J.)), ((Jensen, N. H.)), ((Kamp-Jensen, M.)), ((Bjarnø, H.)), ((Friis, P.)), ((Brewster, D.)) | journal=The Journal of Pharmacy and Pharmacology | title=The systemic availability of buprenorphine administered by nasal spray | volume=41 | issue=11 | pages=803–805 | date= November 1989 | issn=0022-3573 | doi=10.1111/j.2042-7158.1989.tb06374.x}}</ref>
     |InsufflatedROA_Threshold=< 0.2 mg
     |InsufflatedROA_Threshold=< [[Insufflated threshold dose::0.2]] [[Insufflated dose units::mg]]
     |InsufflatedROA_Light=0.2 - 0.4 mg
     |InsufflatedROA_Light=[[Insufflated min light dose::0.2]] - [[Insufflated max light dose::0.4]] mg
     |InsufflatedROA_Common=0.4 - 0.8 mg
     |InsufflatedROA_Common=[[Insufflated min common dose::0.4]] - [[Insufflated max common dose::0.8]] mg
     |InsufflatedROA_Strong=0.8 - 1.5 mg
     |InsufflatedROA_Strong=[[Insufflated min strong dose::0.8]] - [[Insufflated max strong dose::1.5]] mg
     |InsufflatedROA_Heavy=1.5 mg +
     |InsufflatedROA_Heavy=[[Insufflated heavy dose::1.5]] mg +
     |InsufflatedROA_TimelineFile=
     |InsufflatedROA_TimelineFile=
     |InsufflatedROA_TimelineWidth=
     |InsufflatedROA_TimelineWidth=
     |InsufflatedROA_Duration=8 - 14 hours
     |InsufflatedROA_Duration=[[Insufflated min total time::8]] - [[Insufflated max total time::14]] [[Insufflated total time units::hours]]
     |InsufflatedROA_Onset=30 - 60 minutes
     |InsufflatedROA_Onset=[[Insufflated min onset time::30]] - [[Insufflated max onset time::60]] [[Insufflated onset time units::minutes]]
     |InsufflatedROA_Peak=4 - 8 hours
     |InsufflatedROA_Peak=[[Insufflated min peak time::4]] - [[Insufflated max peak time::8]] [[Insufflated peak time units::hours]]
     |InsufflatedROA_Offset=
     |InsufflatedROA_Offset=
     |InsufflatedROA_Aftereffects=1 - 3 days
     |InsufflatedROA_Aftereffects=[[Insufflated min afterglow time::1]] - [[Insufflated max afterglow time::3]] [[Insufflated afterglow time units::days]]


     |SublingualROA=true
     |SublingualROA=true
     |SublingualROA_Collapsed=true
     |SublingualROA_Collapsed=true
     |SublingualROA_Caption='''WARNING:''' Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. <u>[[responsible drug use|See responsible use section]].</u><br> '''[[Disclaimer|DISCLAIMER]]:''' PW's [[dosage]] information is gathered from users and [[Network|resources]] for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
     |SublingualROA_Caption=
    |SublingualROA_Bioavailability= 30%
    |SublingualROA_Bioavailability= 30%<ref name="Mendelson1997">{{cite journal | vauthors=((Mendelson, J.)), ((Upton, R. A.)), ((Everhart, E. T.)), ((Jacob, P.)), ((Jones, R. T.)) | journal=Journal of Clinical Pharmacology | title=Bioavailability of sublingual buprenorphine | volume=37 | issue=1 | pages=31–37 | date= January 1997 | issn=0091-2700 | doi=10.1177/009127009703700106}}</ref>
    |SublingualROA_Threshold=<0.3 mg
    |SublingualROA_Threshold=<=[[Sublingual threshold dose::0.3]] [[Sublingual dose units::mg]]
     |SublingualROA_Light=0.3 - 0.6 mg
     |SublingualROA_Light=[[Sublingual min light dose::1]] - [[Sublingual max light dose::2]] mg
     |SublingualROA_Common=0.6 - 1.3 mg
     |SublingualROA_Common=[[Sublingual min common dose::2]] - [[Sublingual max common dose::4]] mg
     |SublingualROA_Strong=1.3 - 2.4 mg
     |SublingualROA_Strong=[[Sublingual min strong dose::4]] - [[Sublingual max strong dose::8]] mg
     |SublingualROA_Heavy=2.4 mg +
     |SublingualROA_Heavy=[[Sublingual heavy dose::8]]mg +
     |SublingualROA_TimelineFile=
     |SublingualROA_TimelineFile=
     |SublingualROA_TimelineWidth=
     |SublingualROA_TimelineWidth=
     |SublingualROA_Duration=10 - 18 hours
     |SublingualROA_Duration=[[Sublingual min total time::18]] - [[Sublingual max total time::24]] [[Sublingual total time units::hours]]
     |SublingualROA_Onset=40 - 80 minutes
     |SublingualROA_Onset=[[Sublingual min onset time::40]] - [[Sublingual max onset time::80]] [[Sublingual onset time units::minutes]]
     |SublingualROA_Peak=4 - 8 hours
     |SublingualROA_Peak=[[Sublingual min peak time::1.5]] - [[Sublingual max peak time::2]] [[Sublingual peak time units::hours]]
     |SublingualROA_Aftereffects=1 - 3 days
     |SublingualROA_Aftereffects=[[Sublingual min afterglow time::1]] - [[Sublingual max afterglow time::3]] [[Sublingual afterglow time units::days]]


}}
}}

Latest revision as of 18:42, 3 September 2023

SubstanceBox/Buprenorphine
Chemical Nomenclature
Common names Buprenex, Subutex, Butrans, Cizdol, Addnok, Transtec
Systematic name (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
Class Membership
Psychoactive class Opioid
Chemical class Morphinan
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





⇣ Sublingual
Dosage
Bioavailability 30%[1]
Threshold <=0.3 mg
Light 1 - 2 mg
Common 2 - 4 mg
Strong 4 - 8 mg
Heavy 8mg +
Duration
Total 18 - 24 hours
Onset 40 - 80 minutes
Peak 1.5 - 2 hours
After effects 1 - 3 days
⇣ Insufflated
Dosage
Bioavailability 48%[2]
Threshold < 0.2 mg
Light 0.2 - 0.4 mg
Common 0.4 - 0.8 mg
Strong 0.8 - 1.5 mg
Heavy 1.5 mg +
Duration
Total 8 - 14 hours
Onset 30 - 60 minutes
Peak 4 - 8 hours
After effects 1 - 3 days






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

  1. ↑ Mendelson, J., Upton, R. A., Everhart, E. T., Jacob, P., Jones, R. T. (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–37. doi:10.1177/009127009703700106. ISSN 0091-2700. 
  2. ↑ Eriksen, J., Jensen, N. H., Kamp-Jensen, M., Bjarnø, H., Friis, P., Brewster, D. (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–805. doi:10.1111/j.2042-7158.1989.tb06374.x. ISSN 0022-3573. 
Retrieved from "http://psy.st/w/index.php?title=Template:SubstanceBox/Buprenorphine&oldid=134443"